Molecular Partners AG
Company Profile
Business description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Contact
Wagistrasse 14
Schlieren
Zurich8952
CHET: +41 447557700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
159
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
stocks
Our view of ANZ’s strategic plan
stocks
Perplexing buyback from overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,299.00 | 21.90 | 0.24% |
CAC 40 | 8,097.04 | 177.42 | 2.24% |
DAX 40 | 24,249.43 | 12.49 | 0.05% |
Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
FTSE 100 | 9,409.44 | 43.33 | -0.46% |
HKSE | 25,910.60 | 469.25 | 1.84% |
NASDAQ | 22,521.70 | 172.91 | -0.76% |
Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
S&P 500 | 6,644.31 | 10.41 | -0.16% |
S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
SSE Composite Index | 3,912.21 | 46.98 | 1.22% |